IE45873B1 - Polymorph of cimetidine - Google Patents
Polymorph of cimetidineInfo
- Publication number
- IE45873B1 IE45873B1 IE1932/77A IE193277A IE45873B1 IE 45873 B1 IE45873 B1 IE 45873B1 IE 1932/77 A IE1932/77 A IE 1932/77A IE 193277 A IE193277 A IE 193277A IE 45873 B1 IE45873 B1 IE 45873B1
- Authority
- IE
- Ireland
- Prior art keywords
- cimetidine
- suspension
- solvent
- strong
- disc
- Prior art date
Links
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 229960001380 cimetidine Drugs 0.000 title claims abstract description 57
- 239000000725 suspension Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 238000002329 infrared spectrum Methods 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 238000012546 transfer Methods 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000013019 agitation Methods 0.000 claims abstract description 4
- 238000005119 centrifugation Methods 0.000 claims abstract description 4
- 238000004090 dissolution Methods 0.000 claims abstract description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims abstract description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940043265 methyl isobutyl ketone Drugs 0.000 claims abstract description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 4
- 230000010355 oscillation Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- -1 e.g. Substances 0.000 abstract 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003534 oscillatory effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 241000220479 Acacia Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000005147 X-ray Weissenberg Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB3906576A GB1543238A (en) | 1976-09-21 | 1976-09-21 | Polymorph of cimetidine |
| GB271677 | 1977-01-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE45873L IE45873L (en) | 1978-07-24 |
| IE45873B1 true IE45873B1 (en) | 1982-12-15 |
Family
ID=26237687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1932/77A IE45873B1 (en) | 1976-09-21 | 1977-09-21 | Polymorph of cimetidine |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS5340771A (online.php) |
| AU (1) | AU510629B2 (online.php) |
| BE (1) | BE858432A (online.php) |
| CA (1) | CA1096387A (online.php) |
| DE (1) | DE2742531A1 (online.php) |
| FR (1) | FR2364906A1 (online.php) |
| IE (1) | IE45873B1 (online.php) |
| IL (1) | IL52784A (online.php) |
| LU (1) | LU78142A1 (online.php) |
| NZ (1) | NZ184893A (online.php) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56104868A (en) * | 1980-01-24 | 1981-08-20 | Fujimoto Seiyaku Kk | Conversion between polymorphous crystals of cimetidine |
| JPS56164122A (en) * | 1980-05-21 | 1981-12-17 | Fujimoto Seiyaku Kk | Drug composition comprising cimetidine as main agent |
| HU185636B (en) * | 1981-06-26 | 1985-03-28 | Richter Gedeon Vegyeszet | Process for preparing new cimetidine-hydrate /cimetidine-h/ |
| HU185457B (en) * | 1981-09-25 | 1985-02-28 | Richter Gedeon Vegyeszet | Process for preparating cimetidine-z |
| JPS5888366A (ja) * | 1981-11-19 | 1983-05-26 | Fujimoto Seiyaku Kk | グアニジン誘導体の製造法 |
| JPS59128375A (ja) * | 1983-01-10 | 1984-07-24 | Tokawa Tetsuo | イミダゾ−ル系化合物の製法 |
| JPS59130274A (ja) * | 1983-01-14 | 1984-07-26 | Tokawa Tetsuo | イミダゾ−ル系化合物の製法 |
| JPS59130273A (ja) * | 1983-01-14 | 1984-07-26 | Tokawa Tetsuo | イミダゾ−ル系化合物の製造法 |
| HU196184B (en) * | 1986-09-11 | 1988-10-28 | Richter Gedeon Vegyeszet | Process for producing cimetidine-a modification |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1397436A (en) * | 1972-09-05 | 1975-06-11 | Smith Kline French Lab | Heterocyclic n-cyanoguinidines |
| GB1533380A (en) * | 1974-09-02 | 1978-11-22 | Smith Kline French Lab | Process for the preparation of heterocyclic substituted thioureas and h-cyanoguanidines |
| GB1531231A (en) * | 1974-09-02 | 1978-11-08 | Smith Kline French Lab | Process for the production of cyanoguanidine derivatives |
| CA1064940A (en) * | 1975-08-20 | 1979-10-23 | Wilford L. Mendelson | Reduction process for the preparation of 4-(hydroxymethyl) imidazole compounds |
-
1977
- 1977-08-10 NZ NZ184893A patent/NZ184893A/xx unknown
- 1977-08-22 IL IL52784A patent/IL52784A/xx unknown
- 1977-09-06 BE BE180694A patent/BE858432A/xx not_active IP Right Cessation
- 1977-09-14 AU AU28792/77A patent/AU510629B2/en not_active Expired
- 1977-09-15 FR FR7727887A patent/FR2364906A1/fr not_active Withdrawn
- 1977-09-16 JP JP11209377A patent/JPS5340771A/ja active Granted
- 1977-09-19 LU LU78142A patent/LU78142A1/xx unknown
- 1977-09-20 CA CA287,087A patent/CA1096387A/en not_active Expired
- 1977-09-21 DE DE19772742531 patent/DE2742531A1/de not_active Withdrawn
- 1977-09-21 IE IE1932/77A patent/IE45873B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IE45873L (en) | 1978-07-24 |
| IL52784A0 (en) | 1977-10-31 |
| AU2879277A (en) | 1979-03-22 |
| DE2742531A1 (de) | 1978-03-23 |
| AU510629B2 (en) | 1980-07-03 |
| FR2364906A1 (fr) | 1978-04-14 |
| JPS5340771A (en) | 1978-04-13 |
| LU78142A1 (online.php) | 1978-01-17 |
| JPS6222967B2 (online.php) | 1987-05-20 |
| CA1096387A (en) | 1981-02-24 |
| NZ184893A (en) | 1980-11-28 |
| IL52784A (en) | 1980-09-16 |
| BE858432A (fr) | 1978-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5463116A (en) | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them | |
| NO309898B1 (no) | Krystallinsk form I [R-(R*,R*)]-2-(4-fluorfenyl)- <beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptansyrehemikalsiumsalt | |
| JP2017061536A (ja) | キノリン化合物の結晶形及びその製造方法 | |
| BRPI0617477A2 (pt) | mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica | |
| JPH05208943A (ja) | Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶及びその製造法 | |
| KR100544041B1 (ko) | 결정형태의n-(4-트리플루오로메틸페닐)-5-메틸이소옥사졸-4-카복스아미드 | |
| KR20010022097A (ko) | 열역학적으로 안정한1-(4-카바졸릴옥시)-3-[2-(2-메톡시페녹시)에틸아미노]-2-프로판올의 개질물, 이의 제조 방법 및 이를 함유한 약학조성물 | |
| CA1096387A (en) | Process for the production of polymorph of cimetidine | |
| Han et al. | Self-gelation involved in the transformation of resveratrol and piperine from a co-amorphous system into a co-crystal system | |
| HK1040250A1 (en) | New crystal modification n of torasemide | |
| CN105061420B (zh) | 一种jak抑制剂的晶型及其制备方法和应用 | |
| KR101150504B1 (ko) | 이리노테칸 염산염의 신규의 결정형 | |
| IL125732A (en) | Crystalline modification of the compound -1 (-6,2 difluorobenzyl) 1H- - 1, 2, 3 - triazole-4-carboxamide and a medicinal product for the treatment of epilepsy containing it | |
| HK95084A (en) | Polymorph of cimetidine | |
| JPS6234759B2 (online.php) | ||
| EP0009608A1 (en) | N-Phenethylacetamide compounds, processes for their preparation and therapeutic compositions containing them | |
| WO2007063551A1 (en) | POLYMORPHS OF [R-(R*, R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(l-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-lH-PYRROLE-l-HEPTANOIC ACID MAGNESIUM SALT (2: 1) | |
| HK41697A (en) | Pharmaceutical composition comprising a special crystall modification of 1,4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)-3, 5-pyridinedicarbonylic acid-(-2-methoxyethyl)-isopropyl ester | |
| JP2002517398A (ja) | アモキシシリンの結晶性塩の製造方法 | |
| EP2016048A1 (en) | A crystalline form b4 of atorvastatin magnesium and a process thereof | |
| CA1051890A (en) | Esters of theophyllinylacetic acid | |
| EP1473036B1 (en) | Zolpidem hemitartrate solvate | |
| KR100364941B1 (ko) | 1-[5-메탄설폰아미도인돌릴-2-카보닐]-4-[3-(1-메틸에틸아미노)-2-피리디닐]피페라진의신규한결정형태 | |
| AU2013204129C1 (en) | Crystal Form of Quinoline Compound and Process for its Production | |
| CN121226226A (zh) | 一种吲哚布芬新晶型 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK9A | Patent expired |